Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients Following 3 Doses of COVID-19 Vaccine.
Gastroenterology
; 2022 Oct 19.
Article
in English
| MEDLINE | ID: covidwho-2232653
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Vaccines
/
Variants
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
J.gastro.2022.10.010
Similar
MEDLINE
...
LILACS
LIS